Tenaya Therapeutics Prepares New TN-201 Gene Therapy Data for Genetic Heart Disease
SOUTH SAN FRANCISCO, Calif., June 2, 2026 Tenaya Therapeutics announced that it will present new interim clinical data from...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine targeted therapy
SOUTH SAN FRANCISCO, Calif., June 2, 2026 Tenaya Therapeutics announced that it will present new interim clinical data from...
WILMINGTON, Del., May 14, 2026 AstraZeneca announced that the U.S. Food and Drug Administration has approved FASENRA® (benralizumab) for...
CAMBRIDGE, UK, May 14, 2026 AstraZeneca announced positive interim results from the global Phase III VOLGA trial, demonstrating that...
RAMAT-GAN, Israel, May 14, 2026 Galmed Pharmaceuticals Ltd. announced positive results from its first-in-human pharmacokinetics study evaluating the oral...
NEW YORK, May 15, 2026 Protara Therapeutics, Inc. announced positive updated 12-month data from the fully enrolled BCG-Naïve cohort...
CAMBRIDGE, Mass., May 14, 2026 Biogen Inc. has announced promising topline results from its Phase 2 CELIA study evaluating...
NEEDHAM, Mass., October 9, 2025 — Stealth BioTherapeutics Inc. has announced the launch of Mito Assist™, a comprehensive patient...
COPENHAGEN, Denmark, Oct. 9, 2025 – (cGxP.wire) – Adcendo ApS, a biotechnology company pioneering first- and best-in-class antibody-drug conjugates...
